Compare MCB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | EYPT |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 2005 |
| Metric | MCB | EYPT |
|---|---|---|
| Price | $92.74 | $14.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $98.67 | $31.80 |
| AVG Volume (30 Days) | 140.9K | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $11,053,000.00 | $7,539,000.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $3,115.57 |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.66 | $9.65 |
| 52 Week High | $102.04 | $19.11 |
| Indicator | MCB | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 50.02 |
| Support Level | $86.40 | $11.92 |
| Resistance Level | $93.56 | $13.32 |
| Average True Range (ATR) | 2.63 | 0.82 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 49.38 | 57.33 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.